Medicare Opens $50 Obesity Drug Coverage to Millions as 82% of Seniors Remain Unaware
Updated
Updated · CNBC · Jun 28
Medicare Opens $50 Obesity Drug Coverage to Millions as 82% of Seniors Remain Unaware
3 articles · Updated · CNBC · Jun 28
Summary
Starting Wednesday, eligible Medicare beneficiaries can obtain obesity drugs through CMS's Bridge program for a $50 monthly copay, giving millions of older Americans first-time access to the treatments.
82% of adults 65 and older said they were unaware Medicare was about to cover the drugs, according to an early-June survey of more than 2,100 people conducted before CMS extended the program through 2027.
CMS and drugmakers have emphasized outreach to doctors, pharmacists and pharmacies rather than broad public advertising, saying beneficiaries act when benefits are live and the system needs time to prepare.
Enrollment is not automatic: patients must be in Part D, meet eligibility rules, get a prescription and win prior authorization, while some already covered for diabetes, cardiovascular risk reduction or sleep apnea are excluded.
The muted rollout contrasts with past GLP-1 marketing—Novo spent nearly $500 million on Wegovy and Ozempic ads in the first nine months of 2025—and could slow early uptake even as access expands.
What happens to patients when Medicare's temporary obesity drug coverage ends in just 18 months?
With most seniors unaware of new coverage, is the quiet launch a strategy to manage costs or a failure in public outreach?
Medicare’s $50 GLP-1 Bridge Program: Temporary Access, Policy Risks, and the Future of Weight-Loss Drug Coverage for 29 Million Beneficiaries
Overview
The Medicare GLP-1 Bridge Program, launching July 1, 2026, will give Medicare beneficiaries access to GLP-1 weight-loss drugs through a temporary demonstration program. This initiative is designed for CMS to collect real-world data on how these medications are used, their health outcomes, and actual costs, helping to address past challenges in predicting the financial impact of new blockbuster drugs. By gathering this information, CMS aims to inform the creation of a more permanent policy framework for GLP-1 coverage, ensuring future decisions are based on solid evidence and better managing potential budget risks.